Form 4: Nutex Health Director Granted 603 RSUs

Nutex Health Inc. Director Frank E. Jaumot received a grant of 603 Restricted Stock Units, vesting fully on July 14, 2026.

Summary

• Frank E. Jaumot, a Director of Nutex Health, Inc. (NUTX), was granted 603 Restricted Stock Units (RSUs).
• Each RSU represents a contingent right to receive one share of the issuer's common stock, $0.001 par value, upon vesting.
• The RSUs were granted on July 14, 2025, and are scheduled to vest 100% on July 14, 2026.
• If the Reporting Person leaves service with the Company without cause during the vesting period, the RSUs shall vest on a pro-rata basis for the actual time in service.
• Following this reported transaction, Frank E. Jaumot beneficially owns 603 derivative securities (RSUs).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it represents routine director compensation and aligns the director's interests with shareholders through equity ownership.

Positives

• The grant of Restricted Stock Units to a director aligns management's interests with those of shareholders.
• The vesting schedule encourages long-term commitment and retention of the director.

Risks

• The RSUs are subject to a vesting period, and the director must remain in service (or leave without cause for pro-rata vesting) to fully receive the underlying shares.

Future Outlook

The 603 Restricted Stock Units granted to Director Frank E. Jaumot are scheduled to vest 100% on July 14, 2026, contingent on his continued service with the company.

Industry Context

StockSavvy.ai notes that equity compensation, such as Restricted Stock Units, is a common practice across industries to incentivize directors and executives, aligning their financial interests with the long-term performance of the company. This grant to a director at Nutex Health is consistent with standard corporate governance practices for public companies.

Comparison to Industry Standards

• The grant of RSUs to directors is a standard practice in publicly traded companies, comparable to compensation structures seen at healthcare peers like HCA Healthcare or Tenet Healthcare, where equity awards are used to retain and motivate key personnel.
• The vesting schedule of one year is common for such grants, ensuring a period of service before the equity fully vests, similar to practices observed in many S&P 500 companies.

Stakeholder Impact

• Shareholders: The grant of RSUs to a director aligns their interests with shareholders, potentially encouraging decisions that benefit long-term stock performance.
• Director (Frank E. Jaumot): Receives future equity in the company, contingent on continued service.

Next Steps

• The 603 RSUs are expected to vest on July 14, 2026, converting into shares of Nutex Health common stock.

Key Dates

Recommendation

This Form 4 filing details a routine equity compensation grant to a director and does not provide sufficient new information to warrant a change in investment recommendation. It primarily indicates ongoing alignment of director interests with the company's performance.

Keywords

Nutex Health, NUTX, Form 4, Restricted Stock Units, RSU grant, insider transaction, director compensation, equity compensation